CD33 CART AML

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

3 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML). Patients who are between ages 1 to 30 years with relapsed or refractory AML will be eligible for this study.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 215-590-5476.

Eligibility & Criteria

IRB #:
19-016623
Official Title:
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 29 Years
Gender:
All
Study Categories:
Leader
Richard Aplenc

Richard Aplenc, MD, PhD, MSCE